Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19454166 | 0.83 | CYP3A4 (0.31) | CYP3A4TSHRHSD17B10CHRNA7LMNA | |
| SCHEMBL1106419 | 0.81 | CYP2C19 (0.37) | GAACYP3A4TSHRHSD17B10LMNA | |
| SCHEMBL9963385 | 0.81 | ADORA2A (0.38) | CYP3A4TSHRHSD17B10CHRNA7LMNA | |
| SCHEMBL14925526 | 0.78 | CYP3A4 (0.49) | GAAALDH1A1CYP3A4TSHRHSD17B10 | |
| SCHEMBL14925524 | 0.74 | GAA (0.31) | GAA | |
| SCHEMBL1106414 | 0.71 | CHRM3 (0.34) | GAACYP3A4TSHRHSD17B10LMNA | |
| SCHEMBL12938135 | 0.70 | CHRNA7 (0.39) | GAAALDH1A1THRBL3MBTL1CHRNA7 | |
| SCHEMBL798784 | 0.69 | GAA (0.40) | GAA | |
| SCHEMBL13937972 | 0.68 | PIK3R1 (0.33) | CHRNA7PIK3R1PIK3CA | |
| SCHEMBL24836059 | 0.68 | CYP3A4 (0.34) | CYP3A4TSHRHSD17B10LMNABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071475-A1 | UREA DERIVATIVES HAVING PI3K-INHIBITING ACTIVITY | MTOR, STAT3, SLC14A1 | GAA 1336/4885ALDH1A1 3750/4885THRB 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.